



**This document was valid from July 2006 until May 2013.  
It is now superseded by a new version adopted by the HMPC on  
14 May 2013 and published on the EMA website.**

London, 26 October 2006  
Doc. Ref. EMEA/HMPC/340861/2005

**COMMITTEE ON HERBAL MEDICINAL PRODUCTS  
(HMPC)**

FINAL

**COMMUNITY HERBAL MONOGRAPH ON  
*PLANTAGO OVATA* FORSSK., SEMEN**

<b>DISCUSSION IN THE DRAFTING GROUP ON SAFETY &amp; EFFICACY</b>	May 2005 June 2005 September 2005
<b>ADOPTION BY HMPC FOR RELEASE FOR CONSULTATION</b>	20 September 2005
<b>END OF CONSULTATION (DEADLINE FOR COMMENTS )</b>	31 January 2006
<b>REDISCUSSION IN WORKING PARTY ON COMMUNITY MONOGRAPHS AND COMMUNITY LIST</b>	May 2006 July 2006
<b>ADOPTION BY HMPC</b>	13 July 2006

<b>KEYWORDS</b>	Herbal medicinal products; HMPC; Community herbal monograph; well-established use; ispaghula seed; <i>Plantago ovata</i> Forssk.
-----------------	--

**COMMUNITY HERBAL MONOGRAPH ON  
*PLANTAGO OVATA* FORSSK., SEMEN**

**1. NAME OF THE MEDICINAL PRODUCT**

To be specified for the individual finished product.

**2. QUALITATIVE AND QUANTITATIVE COMPOSITION<sup>1,2</sup>**

<p>Well-established use</p> <p>With regard to the marketing authorisation application of Article 10a of Directive 2001/83/EC as amended</p> <p><i>Plantago ovata</i> Forssk. (<i>P. ispaghula</i> Roxb.), semen (ispaghula seed)</p> <ul style="list-style-type: none"> <li>• Herbal substance - dried ripe seeds</li> <li>• Herbal preparation - powdered herbal substance</li> </ul>	<p>Traditional use</p> <p>With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended</p>
--	--

**3. PHARMACEUTICAL FORM**

<p>Well-established use</p> <p>Herbal substance or herbal preparation in solid dosage forms such as granules or powders for oral use. The pharmaceutical form should be described by the European Pharmacopeia full standard term.</p>	<p>Traditional use</p>
--	------------------------

**4. CLINICAL PARTICULARS**

**4.1. Therapeutic indications**

<p><u>Well-established use</u></p> <p>Herbal medicinal product</p> <p>a) for the treatment of habitual constipation;</p> <p>b) in conditions in which easy defaecation with</p>	<p><u>Traditional use</u></p> <p>None</p>
---	---

<sup>1</sup> The material complies with the Ph. Eur. monograph.

<sup>2</sup> The declaration of the active substance(s) should be in accordance with relevant herbal quality guidance.

soft stools is desirable, e.g. in cases of painful defaecation after rectal or anal surgery, anal fissures or haemorrhoids.

#### 4.2. Posology and method of administration

<u>Well-established use</u>	<u>Traditional use</u>
<p><b>Posology</b></p> <p>Oral use</p> <p><i>Adolescents over 12 years of age, adults, elderly</i> 8 - 40 g herbal substance or corresponding amount of herbal preparation (daily dose) in 2 - 3 single doses</p> <p><i>Children from 6 to 12 years of age</i> Half to two-thirds of the adult dose (4 - 25 g herbal substance or corresponding amount of herbal preparation, daily dose) in 2 - 3 single doses.</p> <p><b>Method of administration</b> Mix approximately x g of the [pharmaceutical form] (amount corresponding to 1 g herbal substance) with at least 30 ml of water, milk, fruit juice or similar aqueous liquid; stir briskly and swallow as quickly as possible. Alternatively the herbal substance can be taken and swallowed with sufficient quantity (at least 30 ml per g of herbal substance) of water, milk, fruit juice or similar aqueous liquid; then maintain adequate fluid intake. The product should be taken during the day at least ½ to 1 hour before or after intake of other medicines. The effect starts 12 - 24 hours later.</p> <p>Warning: not to be taken immediately prior to bedtime.</p> <p><b>Duration of use</b> If the constipation does not resolve within 3 days, a doctor or a pharmacist should be consulted. See also section 4.4 Special warnings and precautions for use.</p>	

#### 4.3. Contraindications

<u>Well-established use</u>	<u>Traditional use</u>
<p>Ispaghula seed should not be used by patients with a sudden change in bowel habit that persists for more than 2 weeks, undiagnosed rectal bleeding and failure to defaecate following the use of a laxative.</p>	

Ispaghula seed should also not be used by patients suffering from abnormal constrictions in the gastro-intestinal tract, with diseases of the oesophagus and cardia, potential or existing intestinal blockage (ileus), paralysis of the intestine, or megacolon, diabetes mellitus, which is difficult to regulate.

This product should not be taken by patients who have difficulty in swallowing or any throat problems.

Patients with known hypersensitivity to the active substance should not use ispaghula seed and its preparations.

#### 4.4. Special warnings and precautions for use

##### Well-established use

As there is insufficient experience available, use is not recommended in children below the age of 6 years. Laxative bulk producers should be used before using other purgatives if change of nutrition is not successful.

Ispaghula seed should not be used by patients with faecal impaction and symptoms such as abdominal pain, nausea and vomiting unless advised by a doctor because these symptoms can be signs of potential or existing intestinal blockage (ileus).

If abdominal pain occurs or in cases of any irregularity of faeces, the use of ispaghula seed should be discontinued and medical advice must be sought.

A sufficient amount of liquid should always be taken e.g. 30 ml of water per 1 g of herbal substance.

In the package leaflet, the patient is informed about the following warning:

##### **Warning**

Take each single dose of this product with at least x ml (x is to be replaced by the amount which corresponds to 30 ml per 1 g of the herbal substance or corresponding amount of the herbal preparation) of water or similar aqueous fluid. Taking this product without adequate fluid may cause it to swell and block your throat or oesophagus and may cause choking. Intestinal obstruction may occur if adequate fluid intake is not maintained. If you experience chest pain, vomiting, or difficulty in swallowing or breathing after taking this product, seek immediate medical attention. The treatment of debilitated patients requires medical supervision. The treatment of

##### Traditional use

elderly patients should be supervised.	
--	--

#### 4.5. Interaction with other medicinal products and other forms of interaction

<u>Well-established use</u>	<u>Traditional use</u>
<p>Enteral absorption of concomitantly administered medicines such as minerals, vitamins (B 12), cardiac glycosides, coumarin derivatives, carbamazepine and lithium may be delayed. For this reason the product should not be taken ½ to 1 hour before or after intake of other medicinal products.</p> <p>If the product is taken together with meals by insulin dependent diabetic patients it may be necessary to reduce the insulin dose.</p> <p>Use of ispaghula seed concomitantly with thyroid hormones requires medical supervision because the dose of the thyroid hormones may have to be adjusted.</p> <p>In order to decrease the risk of gastrointestinal obstruction (ileus) ispaghula seed should be used together with medicinal products known to inhibit peristaltic movement (e.g. opioids, loperamide) only under medical supervision.</p>	

#### 4.6. Pregnancy and lactation

<u>Well-established use</u>	<u>Traditional use</u>
<p>No restriction. Laxative bulk producers should be used before using other purgatives if change of nutrition is not successful.</p>	

#### 4.7. Effects on ability to drive and use machines

<u>Well-established use</u>	<u>Traditional use</u>
<p>Not relevant.</p>	

#### 4.8. Undesirable effects

<u>Well-established use</u>	<u>Traditional use</u>
<p>Flatulence may occur with the use of the product, this generally disappears in the course of the treatment. Abdominal distension and risk of intestinal or oesophageal obstruction and faecal impaction may occur, particularly if swallowed with insufficient fluid.</p> <p>Due to the allergic potential of ispaghula, patients</p>	

<p>must be aware of reactions of hypersensitivity including very rare anaphylaxis-like reactions. If other adverse reactions not mentioned above occur, a doctor or a pharmacist should be consulted.</p>	
---	--

#### 4.9. Overdose

<u>Well-established use</u>	<u>Traditional use</u>
<p>Overdose with ispaghula seed may cause abdominal discomfort, flatulence and possibly intestinal obstruction. Adequate fluid intake should be maintained and management should be symptomatic.</p>	

### 5. PHARMACOLOGICAL PROPERTIES<sup>3</sup>

#### 5.1. Pharmacodynamic properties

<u>Well-established use</u>	<u>Traditional use</u>
<p>Pharmacotherapeutic group: Laxatives – Bulk Producers ATC-Code: A 06 AC</p> <p>The active ingredient ispaghula seed consists of the dried ripe seeds of <i>Plantago ovata</i> Forssk. Ispaghula seed is particularly rich in alimentary fibres and mucilages. Ispaghula seed is capable of absorbing up to 10 times its own weight in water. Ispaghula seed consists of 20 – 30 % mucilages, which are located in the episperms. It is partly fermentable (<i>in vitro</i> 72 % unfermentable residue) and acts by hydration in the bowel. Gut motility and transit rate can be modified by ispaghula through mechanical stimulation of the gut wall as a result of the increase in intestinal bulk by water and the decrease in viscosity of the luminal contents or by contact with rough fibre particles. When taken with a sufficient amount of liquid (at least 30 ml per 1 g of herbal substance) ispaghula produces an increased volume of intestinal contents due to its highly bulking properties and hence a stretch stimulus, which triggers defaecation; at the same time the swollen mass of mucilage forms a lubricating layer, which makes the transit of intestinal contents easier.</p> <p><i>Progress of action:</i> Ispaghula seed usually acts within 12 to 24 hours after single administration.</p>	<p>Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.</p>

<sup>3</sup> Scientific data available do not always differentiate the investigated preparations exactly whether the investigated herbal substance was ispaghula husk or seed or psyllium seed and often indicate "psyllium" as investigated herbal substance. If a differentiation was not possible the term "psyllium" is used.

Sometimes the maximum effect is reached after 2 to 3 days.

## 5.2. Pharmacokinetic properties

<u>Well-established use</u>	<u>Traditional use</u>
<p>The material hydrates and swells to form a mucilage because it is only partially solubilised. Polysaccharides, such as those which dietary fibres are made of, must be hydrolysed to monosaccharides before intestinal uptake can occur. The sugar residues of the xylan backbone and the side chains of psyllium are joined by <math>\beta</math>-linkages, which cannot be broken by human digestive enzymes.</p> <p>Less than 10 % of the mucilage gets hydrolysed in the stomach, with formation of free arabinose. Intestinal absorption of the free arabinose is approximately 85 % to 93 %.</p> <p>To varying degrees, dietary fibre is fermented by bacteria in the colon, resulting in production of carbon dioxide, hydrogen, methane, water, and short-chain fatty acids, which are absorbed and brought into the hepatic circulation. In humans, psyllium reaches the large bowel in a highly polymerised form that is fermented to a limited extent, resulting in increased faecal concentration and excretion of short-chain fatty acids.</p>	<p>Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.</p>

## 5.3. Preclinical safety data

<u>Well-established use</u>	<u>Traditional use</u>
<p>There are only data for ispaghula husk and psyllium without defining the exact test preparation available.</p> <p><b>Single dose toxicity</b></p> <p>The LD50 in rats was greater than the highest dose tested corresponding to 3,360 mg/kg ispaghula husk administered by gavage of an aqueous suspension. The LD50 in mice was greater than the highest dose tested corresponding to 2,940 mg/kg ispaghula husk also administered by gavage of an aqueous suspension. These studies were conducted prior to the establishment of good laboratory practices.</p> <p><b>Subchronic toxicity</b></p> <p>Psyllium was fed to rats at levels high as 10 % of the diet for periods up to 13 weeks (three 28-day studies, one 13-week study). Psyllium consumption ranged from 3,876 to</p>	<p><b><i>Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product.</i></b></p>

11,809 mg/kg/day. Because the absorption of psyllium is very limited, histopathological evaluations were limited to the gastrointestinal tract, liver, kidneys and gross lesions without observing any treatment-related effect. Effects considered to be biologically significant and related to psyllium supplementation were lower serum total protein, albumin, globulin, total iron-binding capacity, calcium, potassium, and cholesterol; and higher aspartate transaminase (AST) and alanine transaminase (ALT) activities relative to control. Several of these effects are considered to be secondary effects to others. The reasons for the lower serum total protein, albumin and globulin are not clear, but the absence of any increases in urinary protein, any evidence of gastrointestinal pathology, which could account for protein loss, and any differences in growth or feed efficiency in psyllium fed rats may give evidence that there are no adverse effect of psyllium on protein metabolism.

**Reproductive toxicity**

A rat multigeneration reproduction/teratology study showed no evidence of any adverse effects of psyllium on reproduction or development. Psyllium as 0, 1.25, or 5% (w/w) of the diet was administered in a standard (NIH-07) rat and mouse meal diet *ad libitum* through gestation of the third generation.

A segment II study in rabbits also showed no evidence of any adverse effect. Psyllium as 0, 2.5, 5 or 10% (w/w) of diet was administered in a purine certified rabbit chow diet for days 2 - 20 of gestation.

**Genotoxicity and carcinogenicity**

Tests on genotoxicity and carcinogenicity have not been performed.

**6. PHARMACEUTICAL PARTICULARS**

<p><b><u>Well-established use</u></b></p> <p>Not applicable.</p>	<p>Traditional use</p>
--	------------------------

**7. DATE OF COMPILATION/LAST REVISION**

26 October 2006